Spyre Therapeutics, Inc. announced the initiation of dosing for healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies, SPY002-091 and SPY002-072. This marks a key advancement in the company's pipeline for inflammatory and fibrotic diseases.
Preclinical data for both SPY002 molecules demonstrated picomolar potency and the potential for quarterly or twice-yearly dosing, suggesting improved efficacy and convenience over first-generation anti-TL1As. Interim pharmacokinetic, pharmacodynamic, and safety data from these trials are anticipated in the second quarter of 2025.
The company reported a pro forma cash balance of over $630.1 million as of September 30, 2024, following a recent $230 million financing. This strong financial position provides a cash runway into the second half of 2028, supporting the continued development of its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.